Drug Pricing
Featured Topics
Lead story
Other featured articles
-
Comments to CMS on Proposed Guidance for Coverage with Evidence Development
Eleven Schaeffer fellows cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations on the proposed Coverage with Evidence Development Guidance.
Posted in -
Seminar Series – Inma Hernandez
Inmaculada (Inma) Hernandez is a Professor with tenure at the University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences. She has authored more than 100 scientific articles, including first-authored papers in JAMA, among other leading journals.Â
Posted in -
Disadvantaging Rivals: Vertical Integration in the Pharmaceutical Market
Premiums of Part D beneficiaries enrolled in a plan that is vertically integrated with a PBM increased from 30% to 80% between 2010 and 2018.
Posted in -
Insulin Fills by Medicare Enrollees and Out-of-Pocket Caps Under the Inflation Reduction Act
This study uses data from IQVIA’s National Prescription Audit to assess the association of the Inflation Reduction Act’s cap on cost sharing with insulin fills.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Drug Pricing
Our Work In Drug Pricing
-
Inflation Reduction Act’s Cap on Insulin Out-of-Pocket Costs Boosts Prescription Fills
Published in JAMA, the findings from USC and University of Wisconsin–Madison researchers suggest the policy cut the number of Medicare enrollees who weren’t filling insulin because of cost.
Categorized in -
Blame Capitalism? Why Hundreds of Decades-Old Yet Vital Drugs Are Nearly Impossible to Find
The shortages, which have been going on for years, have typically affected only low-cost generics rather than profitable brand-name drugs.
Categorized in -
Cancer Drug Trastuzumab And Its Biosimilars Compete On Price For Market Share
Using Medicare claims, Schaeffer experts documented US prescribing patterns for originator biologic trastuzumab (Herceptin), a targeted cancer therapy, and five biosimilar entrants since 2019.
Categorized in -
Biosimilars Drug Market Isn’t Broken After All, USC Schaeffer Study Finds
Researchers looked at cancer therapy trastuzumab (Herceptin) and found biosimilars bring competition to the market, with prices declining by more than half for some versions.
Categorized in -
Four Ways to Make Drug Price Negotiations Work for EveryoneÂ
The IRA will be measured not just by how much it can lower prices, but also by whether it continues to encourage drug makers to invest in new treatments.
Categorized in -
Biosimilar Drugs Underutilized Due to Commercial Insurance Restrictions
The first study to examine biosimilar drivers finds commercial insurers limit use in almost 20% of cases.
Categorized in